M&A / Deals Lilly, Gilead lead pharma’s M&A boom BioPharma DiveDeal volume in 2026 is substantially outpacing last year, and activity is being driven by interest in cancer and autoimmune disease drugs.Read full story pharminent May 8, 2026 (Last updated: May 10, 2026) BioPharma Dive Deal volume in 2026 is substantially outpacing last year, and activity is being driven by interest in cancer and autoimmune disease drugs. Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Biogen, Eisai hit with 3-month delay for starting SubQ Alzheimer’s therapyNext: Pulsesight reports positive phase 1 data for PST611 in dry AMD Related Stories M&A / Deals AbbVie climbs post-Allergan M&A peak with Apogee buy pharminent June 22, 2026 M&A / Deals Lilly bets up to $800M for BioArctic’s brain delivery tech pharminent June 22, 2026 M&A / Deals Insilico and SK Bio forge $2.5bn AI neuroimmunity alliance pharminent June 22, 2026
